This is a placebo controlled trial to test the efficacy and safety of daily oral Atogepant in the prevention of episodic migraine. The study will consist of a 4-week screening period, a 12-week treatment period, and a 4-week follow up period for a total duration of 20 weeks. After completion of the lead-in study there is an option to roll into a 9-month open label study.

Subjects must be between 18-80 years old and have at least 4 migraine headache days per month, but no more than 14 headache days a month. Subjects must have tried at least one preventative medication, although cannot currently be using a preventative medication. Use of migraine abortive medications is allowed throughout the study.

Subjects may

receive up to $800 for their participation. All study medication and procedures will be provided at no cost to the participants.